

**Preferred Drug List Committee  
Meeting Agenda, Open Session  
March 10, 2021 11:30am to 1:00pm**

**Meeting Location\***

\*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:

Zoom: <https://us02web.zoom.us/j/83634968853>

Dial: (312) 626-6799 Meeting ID: 836 3496 8853

**Members of the public are required to complete a conflict of interest form if they intend to provide public comments to the Committee. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (March 03, 2021). Please email the completed form to [Annette.Grant@ks.gov](mailto:Annette.Grant@ks.gov).**

**Committee Members**

Jessica Bates, PharmD., BCPS (Chair)  
Emily Blew, PharmD.  
Taylor Gill, PharmD., BCPS  
Katherine Grimsley, M.D.  
Robert Haneke, Pharm.D.

Megan Hedden, PharmD.  
William Pankey, M.D.  
James Rider, D.O.  
Donna Sweet, M.D.  
Wayne Wallace, M.D.

**KDHE-DHCF Staff**

Annette Grant, RPh  
Victor Nguyen, Pharm.D.

**DXC Technology Staff**

Karen Kluczykowski, RPh.  
Harry Vu, PharmD

Kathy Kaesewurm, RN, BSN

- I. Call to Order
  - a. Announcements and Introductions
- II. Review & Approval of Meeting Minutes from 09/09/2020.
- III. Old Business
  - a. Consent Agenda Items
    - i. PDL New Drug Placements
      - 1. AirDuo® Digihaler®
      - 2. ArmonAir® Digihaler®
      - 3. Eysuvis™ Suspension
      - 4. Impeklo™ Lotion
      - 5. Nyvepria™ Injection
      - 6. Sutab® Tablets
    - ii. Committee discussion/Recommendations

#### IV. New Business

- a. Preferred Drug List Committee review and recommendation, regarding which PDL classes would allow for continued use without an annual Non-Preferred PDL prior authorization (PA) renewal being required.
  1. Public Comment
  2. Committee Discussion/Recommendations
- b. Changes to the PDL Committee Meeting Month and Time
  1. Committee Discussion/Recommendations
- c. Request to rename the Migraine Prophylaxis and Treatment PDL Classes
  1. Committee Discussion/Recommendations
- d. PDL Committee feedback regarding the PDL Program.
  1. Public Comment
  2. Committee Discussion/Recommendations

#### V. Adjourn

**\*\*THIS AGENDA IS SUBJECT TO CHANGE\*\***